The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Flagged first, then by citations
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 101–200 of 849
Advances in the management of colorectal cancer: from biology to treatment
Ahmed, S., JOHNSON, K., Ahmed, O., & Iqbal, N. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1928-5 · Cited by 106
Margonis, G. A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M. A., & Pawlik, T. M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4587-z · Cited by 101
Passiglia, F., Bronte, G., Bazan, V., Galvano, A., Vincenzi, B., & Russo, A. D. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.015 · Cited by 103
Bevacizumab: overview of the literature
Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.13 · Cited by 101
Shi, Q., de Gramont, A., Grothey, A., Zalcberg, J. R., Chibaudel, B., Schmoll, H., Seymour, M., Adams, R., Saltz, L. B., Goldberg, R. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5887 · Cited by 100
Self-citationThe use of combinations of monoclonal antibodies in clinical oncology
Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.008 · Cited by 101
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
Cartwright, T. H. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.11.001 · Cited by 99
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis
Brandi, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.519 · Cited by 100
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 99
Approaches to modernize the combination drug development paradigm
Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 94
Therapeutic strategy in unresectable metastatic colorectal cancer
Chibaudel, B., Tournigand, C., André, T., & de Gramont, A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011431592 · Cited by 96
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.606213 · Cited by 90
Lacouture, M. E., Anadkat, M. J., Jatoi, A., Garawin, T., Bohac, C., & Mitchell, E. P. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.12.004 · Cited by 94
Self-citationNew Trends in the Therapeutic Approach to Metastatic Colorectal Cancer
Sánchez-Gundín, J., Fernández-Carballido, A. M., Valdivieso, L. M., Barreda-Hernández, D., & Torres‐Suárez, A. I. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24453 · Cited by 91
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
Tabernero, J. M., García‐Carbonero, R., Cassidy, J., Sobrero, A. F., Cutsem, E. V., Köhne, C.-H., Tejpar, S., Gladkov, O. A., Давиденко, І., Salazar, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0107 · Cited by 89
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Keating, G. M. (2010) · Drugs · doi:10.2165/11205090-000000000-00000 · Cited by 94
Anti-HER agents in gastric cancer: from bench to bedside
Fornaro, L., Lucchesi, M., Caparello, C., Vasile, E., Caponi, S., Ginocchi, L., Masi, G., & Falcone, A. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.81 · Cited by 84
Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
Strickler, J. H., & Hurwitz, H. I. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0003 · Cited by 85
Bronte, G., Silvestris, N., Castiglia, M., Galvano, A., Passiglia, F., Sortino, G., Cicero, G., Rolfo, C. D., Peeters, M., Bazan, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4959 · Cited by 85
Treatment of Metastatic Colorectal Cancer
Davies, J. M., & Goldberg, R. M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.009 · Cited by 86
Wang, F., Chen, G., Zhang, Z., Yuan, Y., Wang, Y., Gao, Y., Sheng, W., Wang, Z., Li, X., Yuan, X., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12639 · Cited by 91
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82
Renaud, S., Romain, B., Falcoz, P., Olland, A., Santelmo, N., Brigand, C., Rohr, S., Guénot, D., & Massard, G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.499 · Cited by 82
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 82
Mechanisms of Immunosuppression in Colorectal Cancer
Zhang, Y., Rajput, A., Jin, N. Y., & Wang, J. (2020) · Cancers · doi:10.3390/cancers12123850 · Cited by 85
Cutsem, E. V., Dicato, M. A., Arber, N., Berlin, J. D., Cervantes, A. M. R., Ciardiello, F., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Geva, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq273 · Cited by 80
Current Progress in Targeted Therapy for Colorectal Cancer
Ortega, J., Vigil, C. E., & Chodkiewicz, C. (2010) · Cancer Control · doi:10.1177/107327481001700102 · Cited by 80
Improving combination cancer therapy: the CombiPlex ® development platform
Tolcher, A. W., & Mayer, L. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0607 · Cited by 80
Roukos, D. H., Katsios, C. G., & Liakakos, T. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.49 · Cited by 80
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M. T., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 84
Peeters, M., & Price, T. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.08.002 · Cited by 80
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012
Ku, G. Y., Tan, I. B., Yau, T. C. C., Boku, N., Laohavinij, S., Cheng, A., Kang, Y., & Lopes, G. D. L., Jr. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70424-2 · Cited by 76
Richman, S. D., Chambers, P. A., Seymour, M., Daly, C. L., Grant, S. L., Hemmings, G., & Quirke, P. (2011) · Europe PMC (PubMed Central) · doi:10.3233/acp-2011-0005 · Cited by 78
Nielsen, D. L., Palshof, J. A., Larsen, F. O., Jensen, B. V., & Pfeiffer, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.006 · Cited by 78
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 81
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Dienstmann, R., Dosso, S. D., Felip, E., & Tabernero, J. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.009 · Cited by 77
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Ng, Q. S., Mandeville, H., Goh, V., Alonzi, R., Milner, J., Carnell, D. M., Meer, K., Padhani, A. R., Saunders, M. I., & Hoskin, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr332 · Cited by 76
Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review
Chibaudel, B., Tournigand, C., Bonnetain, F., Richa, H., Benetkiewicz, M., André, T., & de Gramont, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015572343 · Cited by 75
Kamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 75
Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?
Mise, Y., Kopetz, S., Mehran, R. J., Aloia, T. A., Conrad, C. H., Brudvik, K. W., Taggart, M. W., & Vauthey, J. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4207-3 · Cited by 75
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
Arnold, D., Prager, G. W., Quintela, A., Stein, A., Vera, S. R. M., Mounedji, N., & Taı̈eb, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy038 · Cited by 75
Imai, K., Adam, R. A., & Baba, H. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12276 · Cited by 74
Sundström, M., Edlund, K., Lindell, M., Glimelius, B. L. G., Birgisson, H., Micke, P., & Botling, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-660 · Cited by 74
Karanicolas, P. J., Metrakos, P. P., Chan, K., Asmis, T. R., CHEN, E., Kingham, T. P., Kemeny, N. E., Porter, G. A., Fields, R. C., Pingpank, J., et al. (2013) · Current Oncology · doi:10.3747/co.21.1577 · Cited by 74
Élez, E., Argilés, G., & Tabernero, J. M. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0369-x · Cited by 72
More is less—combining targeted therapies in metastatic colorectal cancer
Punt, C. J. A., & Tol, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.168 · Cited by 76
Napolitano, S., Martini, G., Rinaldi, B., Martinelli, E., Donniacuo, M., Berrino, L., Vitagliano, D., Morgillo, F., Barra, G., De Palma, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0020 · Cited by 72
Translating TRAIL-receptor targeting agents to the clinic
den Hollander, M. W., Gietema, J. A., de Jong, S., Walenkamp, A., Reyners, A. K. L., Oldenhuis, C. N. A. M., & de Vries, E. G. E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.007 · Cited by 71
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2029 · Cited by 72
Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application
Calzetta, L., Page, C. P., Matera, M. G., Cazzola, M., & Rogliani, P. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000951 · Cited by 78
Giessen, C. A., Laubender, R. P., Ankerst, D. P., Stintzing, S., Modest, D. P., Mansmann, U., & Heinemann, V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1515 · Cited by 68
Saltz, L. B., Badarinath, S., Dakhil, S. R., Bienvenu, B. J., Harker, W. G., Birchfield, G., Tokaz, L. K., Barrera, D., Conkling, P., O’Rourke, M. A., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.05.006 · Cited by 71
Self-citationToxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
Eng, C. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.16 · Cited by 70
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
Schmiegel, W., Reinacher-Schick, A. C., Arnold, D., Kubicka, S., Freier, W., Dietrich, G., Geißler, M., Hegewisch-Becker, S., Tannapfel, A., Pohl, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt028 · Cited by 68
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
Baas, J. M., Krens, L. L., Guchelaar, H., Ouwerkerk, J., de Jong, F. A., Lavrijsen, A. P. M., & Gelderblom, H. A. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.004 · Cited by 68
Adelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 72
Correale, P., Marra, M., Remondo, C., Migali, C., Misso, G., Arcuri, F., Vecchio, M. T. D., Carducci, A., Loiacono, L., Tassone, P., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.005 · Cited by 67
Petrelli, F., & Barni, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds289 · Cited by 68
Advancements in the Management of Pancreatic Cancer: 2013
Saif, M. W. (2013) · PubMed · doi:10.6092/1590-8577/1481 · Cited by 67
Ma, Y., Luk, A. W. S., Young, F., Lynch, D. T., Chua, W. M., Balakrishnar, B., SOUZA, P. D., & Becker, T. M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081264 · Cited by 67
Guercio, B. J., Zhang, S., Ou, F., Venook, A. P., Niedzwiecki, D., Lenz, H., Innocenti, F., O’Neil, B. H., Shaw, J. E., Polite, B. N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01019 · Cited by 70
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
Aparicio, J., Esposito, F. M., Serrano, S., Falcó, E., Escudero, P., Ruiz‐Casado, A., Manzano, H., & Montés, A. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123889 · Cited by 71
Management of stage IV rectal cancer: Palliative options
Ronnekleiv‐Kelly, S. M. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i7.835 · Cited by 67
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., Maspero, F., Sauta, M. G., Beretta, G. D., & Barni, S. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.04.006 · Cited by 67
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 69
Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0066 · Cited by 64
Yuan, C., Sato, K., Hollis, B. W., Zhang, S., Niedzwiecki, D., Ou, F., Chang, I.-W., O’Neil, B. H., Innocenti, F., Lenz, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0877 · Cited by 64
Li, T., Wang, C.-C., Zhang, L., & Chen, X. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac503 · Cited by 65
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R., & Eckhardt, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 64
An update on chemotherapy of colorectal liver metastases
Wang, C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.25 · Cited by 62
Gastric cancer in the era of molecularly targeted agents: current drug development strategies
Arkenau, H. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0583-7 · Cited by 62
Ko, A. H., Youssoufian, H., Gurtler, J., Dicke, K. A., Kayaleh, O. R., Lenz, H., Keaton, M. R., Katz, T. L., Ballal, S., & Rowinsky, E. K. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9691-8 · Cited by 62
Chung, C., & Christianson, M. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212474047 · Cited by 62
Shetty, S. J., Thomas, P., Ramanan, B., Sharma, P., Govindarajan, V., & Loggie, B. W. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.10.053 · Cited by 61
Crosstalk between HER2 signaling and angiogenesis in breast cancer
Alameddine, R. S., Otrock, Z. K., Awada, A. H., & Shamseddine, A. I. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff362 · Cited by 58
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 60
Shindoh, J., Nishioka, Y., Yoshioka, R., Sugawara, T., Sakamoto, Y., Hasegawa, K., Hashimoto, M., & Kokudo, N. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5087-5 · Cited by 58
Glimelius, B. L. G., & Cavalli‐Björkman, N. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640828 · Cited by 57
Targeted therapy-induced diarrhea: A review of the literature
Pessi, M. A., Zilembo, N., Haspinger, E. R., Molino, L., Cosimo, S. D., Garassino, M. C., & Ripamonti, C. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.008 · Cited by 58
Wang, Q.-L., Qi, Y., Zhang, D., Gong, C., Yao, A., Xiao, Y., Yang, J., Zhou, F., & Zhou, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2983-9 · Cited by 57
Kandioler, D., Mittlböck, M., Kappel, S., Puhalla, H., Herbst, F., Langner, C., Wolf, B., Tschmelitsch, J., Schippinger, W., Steger, G. G., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.003 · Cited by 56
Lièvre, A., Samalin, E., Mitry, E., Assénat, E., Gestin-Boyer, C., Lepère, C., Bachet, J., Portales, F., Vaillant, J.-N., Ychou, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-347 · Cited by 56
Benson, A. B., Arnoletti, J. P., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Dilawari, R. A., Engstrom, P. F., Enzinger, P. C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0104 · Cited by 56
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 59
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
Bordeau, B. M., & Balthasar, J. P. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0704 · Cited by 56
Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1607 · Cited by 55
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
Aderka, D., Stintzing, S., & Heinemann, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30172-x · Cited by 55
Heskamp, S., Boerman, O. C., Molkenboer‐Kuenen, J. D. M., Oyen, W. J. G., van der Graaf, W. T. A., & van Laarhoven, H. W. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28046 · Cited by 54
Linardou, H., Briasoulis, E. C., Dahabreh, I. J., Mountzios, G., PAPADIMITRIOU, C. A., Papadopoulos, S., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.008 · Cited by 54
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54
Bachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 53
Targeted treatments in colorectal cancer: state of the art and future perspectives
Arnold, D., & Seufferlein, T. (2010) · Gut · doi:10.1136/gut.2009.196006 · Cited by 54
Association of Coffee Intake with Survival in Patients With Advanced or Metastatic Colorectal Cancer
Mackintosh, C., Yuan, C., Ou, F.-S., Zhang, S., Niedzwiecki, D., Chang, I.-W., O’Neil, B. H., Mullen, B. C., Lenz, H.-J., Blanke, C. D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3938 · Cited by 52
You, B., & Chen, E. X. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010395940 · Cited by 55
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
